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Introduction:
One major consideration when developing a drug candidate is the potential for interactions with cellular efflux transporters. One such transporter, P-glycoprotein (P-gp) has been shown to significantly decrease the intestinal absorption of numerous compounds. 1 An accurate screening method early in the drug discovery/development process that can detect which candidates are susceptible to P-gp efflux is a highly valuable tool.
1,2
The Caco-2 assay, using cells derived from a human adenocarcinoma is widely used to assess intestinal permeability, and results from this in vitro system compare favorably with in vivo and in situ data. 3, 4 The apically (luminally) located P-gp is expressed and active in Caco-2 cells, therefore the cell line is employed to evaluate whether a drug candidate is a substrate for this transporter. 5 Previous studies in our laboratories have shown that drug-like molecules with particular chemical groups often used to improve a drug candidate's physicochemical properties can exhibit polarized transport properties that are characteristic of efflux pump substrates. 6 In particular, benzoic acid, amidine, and tetrazole moieties conferred high basolateral to apical permeability compared to apical to basolateral permeability, Young, A.M., Audus, K.L., Proudfoot, J., and Yazdanian, M. (2006) Tetrazole compounds: The effect of structure and charge on Caco-2 permeability. J. Pharm. Sci. 95, 717-725. PMID: 16498570. Publisher's official version: http://dx.doi.org/10.1002/jps.20526. Open Access version: http://kuscholarworks.ku.edu/dspace/.
3 suggesting contributions of polarized transport mechanisms. We have selected tetrazolecontaining compounds to study because they showed the highest degree of polarization. 6 Losartan, an angiotensin II antagonist containing a tetrazole ring (Figure 1 ), has been
shown to be a P-gp substrate. [7] [8] [9] Its poor oral absorption can at least partially be attributed to its affinity for P-glycoprotein, however it appears that other transporters may In this study, currently marketed drugs as well as a selection of synthesized "druglike" compounds were used to assess the effect of structure and charge on Caco-2 cell permeability for molecules containing a tetrazole moiety.
Materials:
Dulbecco's Modified Eagle's Medium (DMEM) buffered with HEPES, heat-inactivated fetal bovine serum, non-essential amino acids, and penicillin-streptomycin were obtained 
Permeability Studies:
Cells were washed with HBSS with or without inhibitor and equilibrated at experimental conditions (4° or 37° C) for 30 minutes. Drug with or without inhibitor was loaded into either the apical or basolateral compartment. Plates were shaken (100 rpm) at experimental conditions, and sampled every thirty minutes for two or three hours depending on the permeability of the compound. Samples were taken from the receiver compartment (300 µL) at each time point and replaced with fresh HBSS with or without inhibitor. For the sodium dependence studies, sodium free salt solution replaced sodium chloride with choline chloride and pH was adjusted with tetramethylammonium hydroxide. 10 The studies at pH=4 were performed in HBSS buffered with 20 mM sodium acetate. The inhibitor concentrations used were as follows: 5 µM for Cyclosporin A, 50
µM for MK-571, and 100 µM for rifampicin, SBP, and CCCP. The concentration of test compounds was either 100 µM or a saturated solution in HBSS (whichever concentration is lower).
LC and LC/MS Detection:
Samples were analyzed using HPLC with an Agilent LC/MSD 1100 instrument. A Zorbax C18 column (4.6 x 150 mm) was used for the LC separation. Some compounds were analyzed using UV detection, while others were analyzed with mass spectrometry (electrospray ionization;single quadrupole). 
Permeability Calculations:
Apparent permeability (P app ) in cm/sec was calculated using the following equation: Student's t test was used to determine the statistical significance. A p value less than 0.05 was considered statistically significant. All experiments were performed in triplicate.
Results:
Selected Compounds: Figure 1 shows the structures of drug-like molecules selected for study. Losartan, valsartan, and cilostazol are commercially available compounds that contain a tetrazole ring. Pemirolast, and compounds A-E were synthesized in our laboratories for comparative purposes. To determine the structural effects of the tetrazole ring, a Additionally, analogues D and E of the previously studied phenyltetrazole C were evaluated to determine the importance of the tetrazole ring for efflux properties. 
Caco-2 Cell Permeabilities:
Apical to basolateral (A to B) and basolateral to apical (B to A) permeability values for each of the chosen molecules are given in Table 1 . A PDR that exceeded 2 was considered a significant enough difference to warrant further study. Losartan, pemirolast and compound C all fit this criterion. Additional Caco-2 cell permeability studies were performed to determine whether the presence of inhibitors of various efflux transporters affected the PDR of each drug or drug-like molecule.
Losartan:
Caco-2 cell permeability values were evaluated in the presence of several inhibitors to determine the type of efflux transporters involved (Table 2) . Lowering the temperature to 4°C essentially eliminates A to B and B to A transport as compared to the control (0.38 x 10 -6 and 3.3 x 10 -6 cm/sec, respectively). CCCP (carbonyl cyanide 3-chlorophenyl hydrazone), a metabolic inhibitor, had no significant effect on PDR.
Although the ratio remained the same, the A to B and B to A permeability values 
Pemirolast:
Permeability values for pemirolast and its carboxylic acid and nitrile analogues, compounds A and B are shown in Table 1 . Pemirolast has a PDR of 5.7, and A and B both have PDRs of 1.0. Table 3 
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Compound C (1-[3-(2H-Tetrazol-5-yl)-benzyl]-1H-benzoimidazole)
One of the drug-like molecules synthesized in our labs showed the highest PDR of any of those screened (Table 1) , with a 66.1 fold higher B to A permeability as compared to A to B. 6 In contrast, closely related structural analogues compounds D and E have PDRs of only 1.1 and 2.2, respectively. By reducing the temperature to 4°C, the B to A permeability of compound C is lowered dramatically from 6.0 x 10 -6 cm/sec to 0.7 x 10 -6 cm/sec ( Table 4 ). The PDR decreased considerably, but B to A permeability is still 
MDCK and MDCK-MDR1 permeabilities:
To determine whether any of polarized permeability observed was due to P-gp, the MDR1 transfected MDCK cell line was employed ( 
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PDR as compared to wild type (3.0 and 0.43, respectively). Compound C has a PDR of 1.3 for both wild type and transfected cells.
Permeability at pH=4.0
Caco-2 cell permeability was measured at pH=4.0 to determine whether compound charge had any effect (Table 6 ). Losartan, Pemirolast, and benzimidazoles C and D all had PDRs of approximately 1.
Monolayer Integrity in the Presence of Inhibitors
Paracellular permeability was measured with radiolabeled mannitol for each of the inhibitors used to confirm that they do not affect the integrity of the monolayer. None of the inhibitors or media used (pH=4.0 and sodium free buffer) caused a significant increase in paracellular permeability when compared to control (Table 7) . Additionally, Table 8 shows the permeability of marker compounds caffeine and lucifer yellow in Caco-2 cells (Table 8 ). There appears to be no significant difference between the values at pH 7.4 and 4.0.
Discussion and Conclusions
The studies presented here show that not all tetrazole-containing compounds are asymmetrically transported in Caco-2 cells (Table 1) Table 8 : Caco-2 cell permeability at pH=4.0 for high (caffeine) and low (lucifer yellow) permeability markers; n=3 for all experiments. Losartan is well established as a P-gp substrate in the literature. [8] [9] [10] Rose and
Audus reported that losartan and other angiotensin II antagonists act as P-gp substrates in the blood-brain endothelial barrier. 7 Soldner and colleagues assert that most of the polarization of losartan in Caco-2 is due to P-gp, however another transporter must also be involved. 8 Our work confirms that losartan is a substrate of P-gp. The PDR is reduced substantially in the presence of cyclosporin A (Table 2) , and the MDR1 transfected cell line shows significant B to A permeability and no detectable permeability in the A to B direction. There was likely some permeability from the apical to basolateral compartments, but it fell below the limits of UV detection for the chosen HPLC method.
Cyclosporin A has been shown to inhibit transporters in addition to P-gp (e.g., MRP7), therefore the resulting PDR maybe not be entirely due to P-gp inhibition. 12 Additionally, the MRP inhibitors MK-571 and rifampicin were able to inhibit efflux pump activity in Caco-2 cells. The MRP family of transporters is not fully characterized, and little is known regarding the substrate specificity of each isoform.
Both inhibitors are known to affect MRP1 and MRP2, but it is likely that other MRPs could be affected by these compounds. Soldner et al. used MRP1 and MRP2 transfected MDCK cells to demonstrate that losartan efflux was not mediated by these transporters. 8 Our work does not directly contradict these findings. Rather, we assert that other MRP transporters may be responsible for asymmetric losartan transport in the Caco-2 cell line. Pemirolast also appears to be a substrate for P-glycoprotein and at least one of the MRP isoforms. As described earlier, the specificity of the MRP inhibitors is unknown, therefore the particular isoform cannot be directly identified. Asymmetric transport in the presence of cyclosporin A was decreased significantly, although not completely (Table 3 ). The MDCK studies show a threefold greater B to A permeability as compared to A to B in the MDR1 transfected cell line. It is important to note that the PDR for the wild type MDCK is 0.43, indicating that A to B transport exceeds B to A by more than twofold (Table 5) 
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Benzimidazole compound C showed the most dramatic difference between A to B and B to A permeability (PDR = 66.1). Like pemirolast, it seems that the tetrazole ring is the portion of the structure primarily responsible for the differences in directional permeability. Compound E, the carboxylic acid analogue of C, has a PDR of 2.2. This is consistent with previous findings in our lab, showing asymmetric transport with tetrazole and carboxyl containing compounds. 6 Inhibition of active transport (4°C and CCCP)
reduced the PDR to 7.0 and 3.8, respectively, suggesting both active and passive/facilitative transport mechanisms. Sodium free medium actually increased the PDR quite significantly, thereby removing facilitative transporters such as OATP from consideration.
Inhibition of P-gp via cyclosporin A results in a small decrease in polarization of compound C, indicating that this transporter is not the primary cause of the asymmetry of transport. MK-571 effectively eliminates any differences between A to B and B to A permeability, while the less-specific rifampicin lowers the PDR from 66.1 to 12.5. SBP exposure produces little change in the polarization of transport (Table 4) .
Aside from efflux transporters, another main consideration is the effect of pH and ionization of the compounds on permeability. The pK a of tetrazoles is in the range of 4-5, similar to that of carboxylic acid groups. 9 Therefore, the structures should be 23 Caco-2 cell permeability studies were performed at pH 4.0 to determine the effect of charge. Surprisingly, all of the compounds showing asymmetric permeability values at 7.4 showed no differences in permeability at acidic conditions. Compounds C and D both had PDRs of 1. At pH 4.0, the permeability in both directions increased significantly (Table 6 ) for all compounds except benzimidazole D. This is reasonable because all the compounds studied with the exception of D go from negatively charged to neutral, therefore passive diffusion across the plasma membrane is much more favorable.
Compound D is neutral under all the experimental conditions, so the passive permeability should not be altered. Literature results have demonstrated that a higher fraction of charged species reduces Caco-2 cell permeability. 15 Our mannitol studies (Table 7) confirm that pH= 4.0 media does not increase the paracellular permeability and thereby artificially increase the numbers during the course of the experiment. As an additional control, the high and low permeability markers (caffeine and lucifer yellow, respectively; Table 8 
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This work demonstrates that certain tetrazole compounds are efflux transporter substrates. All the selected compounds screened in this work seem to have an interaction with a member of the MRP family. The particular isoform is not known due to substrate overlap and prior work that indicates that losartan efflux is not MRP1 or MRP2 mediated. 8 To an extent, losartan and pemirolast also show some interaction with P-gp.
In this case, interaction with the relevant transporter(s) seems to be based on the tetrazole structure recognition as well as the negative charge at physiological pH.
This paper also raises some concerns about the use of tetrazole groups as a replacement for carboxylate groups during the lead optimization process. Data presented here suggest that this substitution could significantly affect the efflux transporter affinity, and therefore the absorption and bioavailability of the candidate.
